Investment Analysts’ Weekly Ratings Changes for Senseonics (SENS)

A number of research firms have changed their ratings and price targets for Senseonics (NASDAQ: SENS):

  • 11/14/2026 – Senseonics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/10/2026 – Senseonics had its price target raised by Mizuho from $18.00 to $20.00. They now have an “outperform” rating on the stock.
  • 11/10/2026 – Senseonics had its price target raised by TD Cowen from $15.00 to $17.00. They now have a “buy” rating on the stock.
  • 11/10/2026 – Senseonics had its price target raised by Barclays from $10.00 to $11.00. They now have an “equal weight” rating on the stock.
  • 11/10/2026 – Senseonics had its “hold” rating reaffirmed by Stifel Nicolaus. They now have a $10.00 price target on the stock, up from $9.00.
  • 11/10/2026 – Senseonics had its “buy” rating reaffirmed by HC Wainwright. They now have a $14.00 price target on the stock.
  • 11/10/2026 – Senseonics was upgraded by Raymond James Financial from “underperform” to “market perform”.
  • 11/4/2026 – Senseonics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 10/27/2026 – Senseonics had its “buy” rating reaffirmed by TD Cowen. They now have a $15.00 price target on the stock.
  • 10/22/2026 – Senseonics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 10/7/2026 – Senseonics is now covered by Barclays. They set an “equal weight” rating and a $10.00 price target on the stock.

Senseonics Price Performance

Shares of NASDAQ:SENS opened at $8.90 on Friday. The company has a 50 day moving average of $9.24 and a 200 day moving average of $7.38. The company has a current ratio of 5.92, a quick ratio of 5.60 and a debt-to-equity ratio of 0.70. The stock has a market cap of $487.54 million, a P/E ratio of -3.87 and a beta of 1.04. Senseonics Holdings, Inc. has a 12 month low of $4.79 and a 12 month high of $13.98.

Senseonics (NASDAQ:SENS – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). The business had revenue of $19.56 million during the quarter. Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. As a group, sell-side analysts forecast that Senseonics Holdings, Inc. will post -2.20 EPS for the current fiscal year.

Insider Buying and Selling at Senseonics

In related news, Director Douglas Roeder bought 17,041 shares of the company’s stock in a transaction on Friday, November 13th. The stock was acquired at an average cost of $10.32 per share, for a total transaction of $175,863.12. Following the completion of the transaction, the director directly owned 189,712 shares in the company, valued at $1,957,827.84. This trade represents a 9.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.70% of the company’s stock.

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.

Featured Stories

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.